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Abstract
This ECCO topical review of the European Crohn’s and Colitis Organisation [ECCO] focused on 
prediction, diagnosis, and management of fibrostenosing Crohn’s disease [CD]. The objective was 
to achieve evidence-supported, expert consensus that provides guidance for clinical practice.
Key Words:  Stricture; management; consensus
1. Introduction
The Crohn’s disease [CD] course is frequently complicated by intes-
tinal strictures, which can be fibrotic, inflammatory, or mixed, lead-
ing to stenosis and ultimately symptomatic obstruction.1,2 Fibrosis is 
a consequence of local chronic inflammation and is characterised by 
excessive extracellular matrix [ECM] protein deposition produced 
by activated myofibroblasts.3,4 Despite recent advances in the patho-
physiological understanding of CD and a significant improvement in 
anti-inflammatory therapies, mechanisms driving the development 
of complications of the disease, including the formation of fibrotic 
strictures, are less well understood. No specific anti-fibrotic therapy 
exists.5 Despite the therapeutic advances in the treatment of inflam-
matory bowel disease [IBD] in the past two decades, the incidence of 
intestinal strictures in CD has not significantly changed.6,7,8,9,10 There 
is paucity of data in this area and currently no standard exists that 
can guide clinicians dealing with this condition.
This led the European Crohn’s and Colitis Organisation [ECCO] 
to generate a topical review consensus group on stricturing CD. 
Given the paucity of prospective controlled data in this area, a 
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topical review is distinct from the ECCO consensus guidelines and is 
intended to provide guidance in clinical areas which lack evidence. 
To organise the work, subgroups were classified into three major 
topics—prediction, diagnosis, and management. The working par-
ties performed a systematic literature search of their topic with the 
appropriate keywords, using Medline/Pubmed and the Cochrane 
database, as well as their own files. The evidence level [EL] was 
graded according to the 2011 Oxford Centre for Evidence-Based 
Medicine [http://www.cebm.net/index.aspx?o=5653]. Provisional 
statements were then posted on a weblog. Discussions and exchange 
of the literature evidence among the working party members was 
then performed on the weblog. Two preliminary voting rounds fol-
lowed by revision of the statements were performed. The working 
parties met in Barcelona on February 18, 2015 to agree on the state-
ments. A statement was accepted after agreement by at least 80% of 
participants, termed a Current Practice Position, and numbered for 
convenience in the document.
This paper reflects a joint effort by gastroenterologists, radiolo-
gists, colorectal surgeons, and basic scientists. It provides guidance 
on the prediction, detection, and management of strictures in patients 
with CD. The group leaders and their working parties wrote the final 
section of each subgroup. Statements are intended to be read in con-
text with qualifying comments, and not read in isolation. The final 
text was edited for consistency of style by the steering committee [FR 
and AD] before being circulated and approved by the participants. In 
several areas the level of evidence is generally low, which reflects the 
paucity of randomised controlled trials. Consequently expert opin-
ion is included where appropriate.
2. Prediction of fibrostenosing Crohn’s disease
2.1. Definitions
The natural history and behaviour of CD are highly heterogene-
ous. Even though the most common initial presentation of CD is 
purely uncomplicated inflammatory disease, within 10 years of diag-
nosis more than 70% of CD patients develop a stricturing or per-
forating complication.11,12,13,14 More than one-third of CD patients 
develop a distinct fibrostenosing phenotype manifested by progres-
sive narrowing of the bowel lumen and clinical signs of intestinal 
obstruction.11,15,16 Stricturing and perforating disease, which may co-
exist in the same patient, represent the main indication for surgery in 
CD patients.17,18 Disease recurrence at the site of anastomosis, how-
ever, is common, and recurrent stricture formation may also occur.19
CD is a dynamic disorder whose phenotype may evolve with 
time.15 Whereas the location of inflammation is a relatively stable 
clinical feature, changes in disease behaviour can occur throughout 
the disease course.11,12,14,16 Approximately 30–50% of the patients 
already have stricturing or penetrating disease at the time of diagno-
sis, and of those with uncomplicated disease at the time of diagnosis 
about half will then develop either stricturing or penetrating com-
plications during follow-up.14 Intestinal fibrosis and strictures, given 
the transmural nature of CD, affect all layers of the bowel wall with 
histomorphological thickening.
An overlap may exist between stricturing and penetrating disease, 
since internal fistulae may complicate long-standing intestinal ste-
nosis, and many patients undergoing surgery for intestinal obstruc-
tion will be found to have entero-enteric fistulae.20,21,22 Fistulae are 
thought to develop in regions of full-thickness bowel wall inflamma-
tion in a high-pressure region upstream from a stricture,17,23 but pro-
spective data supporting this are missing. In one study, the positive 
predictive value of fistulae in predicting strictures was 86.2%.24 It is 
also widely believed that strictures, once present, are gradually pro-
gressive over time, but longitudinal data to confirm this are lacking.
The most common locations of clinically apparent strictures are 
the ileum and the ileocolonic region, presumably due to the smaller 
diameter of the ileum relative to the colon.25,26 However, strictures 
can appear at any site affected by CD, including the upper gastro-
intestinal tract, the colon, and the rectum. The frequency and loca-
tion of strictures probably follow the distribution of inflammation: 
40–55% terminal ileum and colon, 15–25% colon alone, 25–40% 
exclusively ileum, and up to 10% in the upper gastrointestinal 
tract; but data supporting this hypothesis are lacking.27,28 There is 
no relationship between symptoms and progression of the intestinal 
lesions, since strictures and fistulae may develop for several years 
with only mild symptoms or, in some cases, without any symptoms 
at all.16
2.2. Clinical predictors
It is currently unknown which CD patients will develop a fibros-
tenotic disease phenotype and in what time frame these changes may 
occur. This knowledge is crucial for understanding the pathophysi-
ology of the disease.5,12,29,30 The ability to stratify CD patients into 
at-risk populations can allow for determination of the follow-up 
schedule and the intensity of observation required in patients with a 
higher versus lower likelihood of fibrostenotic changes.
No specific and accurate clinical predictors or clinical diagnostic 
tools for intestinal fibrosis exist, and to date no genetic or serological 
marker of fibrosis is in routine clinical use. Clinical features and bio-
markers have not been shown to be strictly specific for fibrostenosis, 
but rather represent a complicated or disabling CD course.16,18,30
Several clinical factors, including CD diagnosis made under 
the age of 40 years, need for steroid therapy at diagnosis, perianal 
fistulising disease, weight loss > 5 kg, early use of azathioprine or 
anti-tumour necrosis factor [TNF] therapy, smoking, terminal 
ileal disease, and deep mucosal ulceration, have been identified as 
Current Practice Position on Fibrosis 1:
Fibrostenosing Crohn’s disease is defined by persistent lumi-
nal narrowing and can include obstructive symptoms [EL 5]
Current Practice Position on Fibrosis 2:
Intestinal fibrosis is a common and serious complication of 
Crohn’s disease, which can occur at any time during the dis-
ease course [EL3]. Intestinal fibrosis, which affects all layers of 
the bowel wall, is characterised by extracellular matrix [ECM] 
protein accumulation and mesenchymal cell expansion [EL3]
Current Practice Position on Fibrosis 3:
Intestinal fibrosis can result in stricturing Crohn’s disease. 
Stricturing and penetrating disease can commonly co-
exist in the same patient [EL4]
Current Practice Position on Fibrosis 4:
No accurate and specific predictor for intestinal fibro-
sis exists [EL5]. Clinical features and biomarkers are not 
strictly specific for fibrostenosis, but rather predict a com-
plicated or disabling Crohn’s disease course [EL3]
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predictive of a more aggressive and complicated disease, rather 
than an underlying predisposition for intestinal fibrosis, strictures, 
and obstruction.2,18,30,31,32,33,34,35,36,37,38 CD classifications, such as the 
Vienna and Montreal Classifications, merely identify fibrosis after 
it has become clinically significant, so that these clinical catego-
ries are frequently not predictors of disease phenotype but simply 
descriptions of disease behaviour well after the complication has 
occurred.26,39
2.3. Imaging predictors
Currently, no imaging modality specifically predicts the CD phe-
notype.18,30 Barium small bowel follow-through can only determine 
the extent and severity of luminal narrowing. Cross-sectional imag-
ing techniques, such as computed tomography enterography [CTE] 
and magnetic resonance enterography [MRE], are insufficient as 
they only depict one specific point in time. They are diagnostic of 
a stricture [see below], but not predictive. Endoscopy [colonoscopy, 
double-balloon endoscopy] can detect mucosal lesions and lumi-
nal narrowing—ie a stricture after it is already established32—and 
to date no histological feature predicting specifically fibrostenosing 
CD has been described. To assess the disease progression in CD, a 
longitudinal tool, the Lémann score, has been proposed to measure 
the progressive and cumulative structural bowel damage, including 
fibrosis.40,41 This score could be an effective tool to assess fibroste-
nosing CD as it combines different techniques [MRE, endoscopy], 
depending on the location of the disease.
2.4. Genetic and epigenetic predictors
The hypothesis of a genetic background responsible for the 
stricturing behaviour in CD is supported by the re-occurrence of 
intestinal strictures in some CD patients undergoing intestinal resec-
tion compared with CD patients who never develop a stricture in a 
lifespan.18,29,30 Fibrosis is a dynamic and multifactorial process and 
develops by interactions between genetic and environmental factors, 
with different genetic polymorphisms influencing fibrosis in animal 
models and human case–control studies. Studies suggest that vari-
ants of genes encoding immunoregulatory proteins, pro- and anti-
inflammatory cytokines, and fibrogenic factors may impact on CD 
intestinal fibrosis.30,42,43,44
Variants in the nucleotide-binding oligomerisation domain con-
taining 2 [NOD2] gene in CD with/without variants of Toll-like 
receptors [eg TLR4] or autophagy-related-16L1 [ATG16L1] have 
an increased risk of small bowel fibrostenosis.45,46,47,48 Fibrostenotic 
CD appears also to be linked to other genetic variants such as those 
in the interleukin 23 receptor [IL23R] gene, chemokine fractalkine 
receptor CX3CR1 gene, matrix metalloproteinase [MMP]-3 gene, or 
rs1363670 locus near the interleukin [IL]12B gene.48,49,50,51,52 Gene 
variants are promising markers, but their population frequency is 
low and they exhibit incomplete penetrance. Carrying at least one 
NOD2/CARD15 variant increased the risk of stenosing CD (odds 
ratio [OR]: 1.94; 95% confidence interval [CI]: 1.61–2.34) and, 
more prominently, the risk of small bowel involvement [OR: 2.53; 
95% CI: 2.01–3.16].45,47 Furthermore, CD patients carrying NOD2 
gene variants have an increased need for surgery due to stricturing 
disease, and a higher rate of postoperative recurrence.46 Toll-like 
receptor variants, especially TLR4, are associated with small bowel 
fibrostenotic disease.30 Two polymorphisms of the chemokine frac-
talkine receptor CX3CR1 are associated with fibrostenotic CD, inde-
pendently of NOD2.50,52 Variants in the IL23R gene are associated 
with CD fibrosis, merely ileal disease.49 Matrix metalloproteinases 
[MMPs] are endopeptidases involved in extracellular matrix [ECM] 
degradation, and tissue inhibitors of metalloproteinases [TIMPs] 
preserve ECM. Single nucleotide polymorphisms [SNPs] in MMP-3 
increase the risk of stenotic complications in CD.51 Currently the 
routine use of genetic testing for the prediction of fibrostenosing CD 
is not recommended.
Epigenetics may be defined as mitotically heritable changes in 
gene function, not explained by changes in DNA sequence.53 The 
main epigenetic mechanisms include DNA methylation, histone 
modification, RNA interference, and the positioning of nucleosomes. 
Micro RNAs [miRNA] are small, noncoding RNAs of 18–25 nucleo-
tides that regulate gene and protein expression by repressing specific 
target genes post-transcriptionally; miRNA-200a and miRNA-200b 
are over-expressed in the serum of fibrostenosing CD subjects.54 It 
has been demonstrated that levels of miR-29b are reduced in the 
mucosa overlying strictured gut in CD patients, and that collagen 
up-regulation induced in vitro by transforming growth factor β 
[TGF-β] in CD myofibroblasts can be prevented by miR-29b trans-
fection. Moreover, serum levels of miR-29 were found to be lower in 
patients with stricturing CD compared with those without strictures, 
thus highlighting the potential usefulness of miR-29 as a future bio-
marker of fibrostenosing disease.55 Recently, it has been shown that 
serum levels of miR-19a/b are reduced in CD patients with a fibros-
tenosing phenotype.56
 Of note, in a multivariate analysis the association between miR-
29b and a stricturing phenotype was found to be independent of 
confounding clinical variables such as disease duration and the pres-
ence of ileal disease.55 Currently the routine use of epigenetic testing 
for the prediction of fibrostenosing CD is not recommended.
2.5. Serological predictors
A number of circulating antibodies directed against microbial pep-
tides have been detected in CD patients, such as anti-Escherichia coli 
outer membrane protein C antibodies [anti-OmpC], anti-Pseudomonas 
associated sequence I2 antibodies [anti-I2], anti-bacterial flaggelin 
CBir1 antibodies [anti-CBir1], and anti-glycan antibodies which include 
anti-Saccharomyces cerevisiae antibodies [ASCA], anti-chitobioside car-
bohydrate IgA antibodies [ACCA], anti-mannobioside carbohydrate 
IgG antibodies [AMCA], anti-laminarin carbohydrate antibodies [anti-
L], and anti-chitin carbohydrate antibodies [anti-C].57,58,59,60 These anti-
bodies are supposed to originate from an abnormal immune response 
Current Practice Position on Fibrosis 5:
Cross-sectional imaging, endoscopy, or histology cannot pre-
dict the development of fibrostenosing Crohn’s disease [EL5]
Current Practice Position on Fibrosis 6:
The presence of several genetic variants [alone or in com-
bination] is primarily associated with small bowel Crohn’s 
disease and a fibrostenotic phenotype [EL1 4]
Current Practice Position on Fibrosis 7:
Crohn’s disease patients with a stronger humoral immune 
response towards microbial components are more likely to 
develop earlier complicated Crohn’s disease, including fibro-
stenosing disease [EL1-3]
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against the luminal microbiota.61 It has been demonstrated that in both 
adult and paediatric CD patients, serum antimicrobial antibodies are 
qualitatively and quantitatively associated with disease progression 
to fibrostenosing/fistulising complications and increased need for sur-
gery.30,62,63,64,65,66,67,68 A recent meta-analysis, based on 11 studies, focused 
on four antibodies [ASCA, anti-OmpC, anti-I2, and antiCBir1]. ASCA 
showed the highest sensitivity, whereas anti-OmpC showed the highest 
specificity for complications and surgery. Moreover, the analysis of at 
least two antimicrobial antibodies was more effective than any single 
antibody in predicting disease progression towards complications.69 
However, none of the above-mentioned antibodies has been shown to 
be able to discriminate fibrostenotic from penetrating behaviour [or 
specifically predict fibrostenosing CD], nor thus to predict stricture 
development in CD patients.70,71
A prospective paediatric study showed that the risk of develop-
ing a stricturing/penetrating phenotype was 11-fold increased in 
CD patients with serological positivity for anti-CBir1, anti-OmpC, 
anti-I2, and ASCA in comparison with seronegative children.63 These 
findings were confirmed in a subsequent larger study conducted 
through the detection of serum anti-CBir1, anti-OmpC, and ASCA.66 
In a small cohort study using adult patients, the presence of anti-
glycan antibodies was predictive of a more complicated CD course 
without predicting fibrostenosis specifically.59 Further prospective 
studies are required to clarify whether circulating antibodies, alone 
or in conjunction with other biomarkers, can be used to predict the 
disease course and the development of strictures in CD.
A number of ECM molecules and growth factors have been 
investigated in the serum of CD patients as possible biomarkers 
of intestinal fibrosis in CD patients, including fibronectin, collagen 
subtypes or propeptides, laminin, MMPs or TIMPs, basic fibroblast 
growth factor [bFGF], and human chitinase 3-like 1 [also known 
as YKL-40].71,72 None of these markers to date has been shown to 
be predictive of fibrostenosing CD. Serum YKL-40 levels, a growth 
factor secreted by activated macrophages and neutrophils, which 
stimulates myofibroblasts to produce collagen,73 is higher in CD 
patients with a fibrostenosing phenotype, although these results 
derive from studies conducted on a relatively small numbers of 
patients.72,74,75 Further prospective studies are required to clarify 
whether ECM molecules and growth factors can be used to predict 
the disease course and the development of strictures in CD.76,77
3. Diagnosis of fibrostenosing Crohn’s disease
Ultrasonography [US], CTE, and MRE have high sensitivity and 
specificity for the diagnosis of stenosis affecting the large or small 
bowel, and the respective accuracies are similar between US, CTE, 
and MRE.78 Whereas the diagnostic accuracy of MRE and CTE 
requires the use of luminal contrast and anti-peristaltic agents to 
avoid misdiagnosis, their use is not necessary in US for detecting 
stenosis, although their detection increases when oral contrast is 
administered.79
Inflammation and fibrosis in CD are transmural, and thus 
cannot be accurately assessed by endoscopy. In contrast, cross-
sectional imaging can detect transmural abnormalities. Classically, 
CD-associated strictures have been divided into inflammatory 
and fibrotic in the hope of being able to stratify patients for anti-
inflammatory therapies. This differentiation seems unrealistic as, 
in different published series correlating imaging findings with 
histopathology, most strictures have a mixed pattern, with both 
inflammatory and fibrotic components. It is noteworthy that only 
few strictures were classified as ‘purely inflammatory’ or ‘purely 
fibrotic’ at histopathology. Most of them had an important overlap 
of different degrees of fibrosis and inflammation,18,80,81,82,83,84,85,86,87 
and this overlap represents an important challenge for detecting 
and quantifying fibrosis deposition in the bowel wall. An addi-
tional difficulty is the fact that absence of radiological findings of 
inflammation in a stricture does not predict the presence of tissue 
fibrosis.80
Only few studies have focused on the identification of inde-
pendent predictors of fibrosis of the bowel wall by cross-sectional 
imaging. The US stratified echo pattern [different echogenicities in 
different bowel wall layers] at the site of strictures has been asso-
ciated with collagen deposition, but these data have not been fur-
ther validated.88 Chiorean et al. found that the presence of fibrosis 
was associated with stenotic lesions detected by CTE, but did not 
provide any information regarding the degree of inflammation and 
fibrosis in stenotic lesions.81 MR has superior soft tissue contrast 
for bowel wall tissue characterisation. Two studies using MRE with 
T1 and T2 conventional sequences produced conflicting results for 
fibrosis characterisation using T2 signal, wall thickness, and pattern 
of gadolinium enhancement.82,87 A more recent publication revealed 
that the percentage of gain using gadolinium enhancement between 
70 s and 7 min on MRE parallels the degree of fibrosis regardless of 
the degree of inflammation, thus being a reliable method for detect-
ing the presence of severe fibrosis for both stenotic and non-stenotic 
segments. This last study proposed a novel classification of stenosis 
combining different degrees of fibrosis and inflammation, based on 
gain of enhancement and presence of ulcers, respectively.84 In spite 
of the efforts to detect and quantify fibrosis in the bowel wall and its 
association to bowel irreversible damage,89 the clinical significance 
of fibrosis and, in particular, its prediction for need of surgery have 
not been established.
Novel imaging modalities are not routinely used in clinical prac-
tice and may be subject to limitations in standardisation of tech-
niques or in post-processing. MR with dynamic contrast enhanced 
[DCE] technique identified in humans a correlation between fibro-
sis, and maximum enhancement and initial slope of increase.86 
Magnetisation transfer MR [MT-MR] potentially is more sensitive 
than conventional MR to changes in collagen content. MT-MR 
imaging has good correlation with the degree of collagen deposition 
on the colonic wall in a rat model regardless the degree of inflam-
mation.90,91 Lastly, US elastography [USE] offered promising results 
for differentiating different degrees of fibrosis deposition using ani-
mal models.92,93 USE detected in ex vivo human bowel specimens 
an increase in shear wave speed measurements when transmural 
Current Practice Position on Fibrosis 8:
Cross-sectional imaging has high sensitivity and specific-
ity for the diagnosis of stenosis affecting the small bowel 
or the colon [EL  2]. Optimal distension by luminal oral 
contrast and anti-peristaltic agents is recommended to 
avoid misdiagnosis of strictures on CTE or MRE [EL 3]
Current Practice Position on Fibrosis 9:
Both inflammation and fibrosis are often present to 
varying degrees in symptomatic strictures, and cross-
sectional imaging using ultrasonography, CT or MR may 
assist in identifying inflammation in stenotic segments 
[EL  3]. However, currently no cross-sectional imaging 
modality is able to determine the clinical significance of 
the fibrotic component of the stricture [EL 3]
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intestinal fibrosis was present. However, the same results suggested 
that USE might be less capable in differentiating non-transmural 
mild-to-moderate fibrosis from early, predominantly inflammatory 
disease.94
A biomarker defined as ‘a characteristic that is objectively meas-
ured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic 
intervention’95 would be desirable to specifically assess the presence 
and degree of intestinal fibrosis. Given their stability, genetic mak-
ers appear to be promising candidates in fibrostenotic CD.71 NOD2 
gene variants were evaluated as prognostic markers for stricturing 
CD [see above].45 Specificity, however, is low, given that alleles were 
reported to be associated with an ileal disease manifestation and fis-
tulising complications.45 Serum antibodies directed against microbial 
peptides are associated with a more complicated CD course, but not 
specifically with a fibrostenotic phenotype. Available studies were 
not performed to differentiate between stricturing and penetrating 
disease complications or did not reach high specificity rates.70,71,96,97
Intestinal strictures characteristically display thickening of all 
layers of the intestinal wall. Histological specimens demonstrate 
islands of smooth muscle cells in the submucosa with dense colla-
gen deposition as well as disruption and expansion of the muscularis 
mucosa.4,98,99,100 Collagen septa extend through a disorganised and 
thickened muscularis propria. Collagen is the major ECM compo-
nent and a number of subtypes, each with different functions, have 
been identified. Strictured intestine is characterised by an increase 
in total collagen, and also in the relative amount of types III and 
V. Type III collagen has a greater propensity for contraction. During 
normal wound healing, when collagen deposition is rapid, the 
ratio of type III collagen to type I  collagen is increased. This may 
be defined as the early stage of fibrosis, characterised by an increase 
in the accumulation of collagen type III in relation to collagen type 
I. In contrast, during the late stage of fibrosis when active collagen 
deposition diminishes, the ratio of type III collagen to type I collagen 
decreases.101 Moreover, in CD a significant increase in submucosal 
type III collagen fibre content has been reported in stenosed intestine, 
with a particular increase in the outer aspect of the submucosa.102 
This suggests that type III collagen, present in the thickened small 
bowel, may contribute to the functional significance of stenosis by 
reducing the compliance of the submucosa. Fibronectin, a structural 
glycoprotein, is also over-expressed at sites of CD strictures. Tenascin, 
a component of the ECM synthesised by fibroblasts, smooth muscle 
cells, and myofibroblasts, is highly increased in inactive CD.103 In the 
normal colonic mucosa, immunoreactivity for tenascin is confined to 
the basement membrane of the intercryptal surface epithelium and 
the muscularis mucosa. It is not normally present around the crypts.99
Accumulation of myofibroblasts and alterations of the nerves 
induce fibromuscular obliteration of the submucosa, associated 
with thickening of the muscularis propria, which results in motility 
disorders.104,105 Muscularisation of the submucosa is a common fea-
ture of long-term ‘burnt-out’ CD.106 Obliterative muscularisation of 
the submucosa [OMUS] has been observed in about one-third of 
small intestinal resection specimens of CD, usually in stricturing dis-
ease.104 OMUS is especially associated with small bowel strictures, 
which are themselves closely associated with submucosal fibrosis.106 
Hypertrophy of intestinal muscle secondary to intestinal obstruction 
is associated with increase in collagen content, particularly in the 
muscular layer.
Excessive ECM deposition and its abnormal contraction lead to 
scar formation, tissue distortion, and ultimately intestinal obstruc-
tion. Furthermore, histological studies indicate that the amount of 
fibroblast islands within CD-associated strictures correlates with 
the expression of profibrotic cytokines and extracellular matrix 
proteins.107,108,109 To date, no validated histopathological scoring sys-
tem is available to grade the severity of intestinal fibrosis.18 Clinical 
scoring systems correlate to some degree with intestinal inflamma-
tion, but not with fibrosis. In fact, the occurrence of strictures can 
confound the CD activity index. This lack of any standardised scor-
ing system for histological or clinical fibrosis makes comparisons 
between existing studies impossible.
4. Management of fibrostenosing Crohn’s 
disease
4.1. Medical management of fibrostenosing Crohn’s 
disease
CD patients with suspicion for intestinal obstruction should be 
managed by a multidisciplinary team consisting of a gastroenter-
ologist, colorectal surgeon, radiologist, and if needed a pathologist. 
These patients should be hospitalised and treated with gastrointesti-
nal nasogastric decompression, bowel rest, intravenous fluids [0.9% 
saline or lactated Ringer’s solution for intravascular volume repletion], 
and electrolyte replacement guided by test results. Patients with signs 
of peritonitis should be seen by a surgeon immediately. The patients 
should undergo evaluation with cross-sectional imaging to assess a pos-
sible stricture for location, length, the degree of concomitant inflamma-
tion, and accompanying features, such as abscess, phlegmon, or signs 
of malignancy since this affects the management approach [see below].
Current Practice Position on Fibrosis 10:
The presence and degree of fibrosis cannot be evaluated 
by biomarkers, endoscopy, or histology [EL5]
Current Practice Position on Fibrosis 11:
No validated histopathological scoring system is avail-
able to grade the severity of intestinal fibrosis [EL5] Current Practice Position on Fibrosis 12:
Patients with confirmed intestinal obstruction should be 
hospitalised and treated by a multidisciplinary team [EL5]
Current Practice Position on Fibrosis 14:
Patients should undergo evaluation to assess the pres-
ence of inflammation in the stricture. Anti-inflammatory 
therapy should only be considered if the stenosis has an 
inflammatory component [EL4]
Current Practice Position on Fibrosis 13:
Management of stricturing Crohn’s disease depends on 
location/length, the degree of concomitant inflammation, 
and accompanying features, such as abscess, phlegmon, 
or dysplasia [EL3]
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In addition to the above mentioned conservative management, 
traditionally intestinal strictures in CD have been treated by oral and 
intravenous corticosteroids and, in the case of intractable symptoms, 
bowel resection. With the emergence of immunosuppressants, such 
as azathioprine [AZA]/6-mercaptopurine [6-MP] and biologicals [eg 
anti-TNF], additional medical therapy options are available.110
At the current time, a variety of modalities are used to try 
to discriminate medically responsive strictures with an inflam-
matory component from those without, such as the above men-
tioned imaging [CTE, MRE] and laboratory [CRP, ESR] and 
stool [faecal calprotectin] biomarkers. Despite widespread use 
of corticosteroids, the data supporting their utility are limited. 
Yaffe and colleagues reported their experience with non-oper-
ative management of acute small bowel obstruction in 26 CD 
patients. In all but one patient, the obstruction was relieved 
within 72 h using a regimen that included clear liquid diet, small 
bowel tube, total parenteral nutrition, prednisone, intravenous 
fluids, and intravenous crystalline adrenocorticotropic hormone 
[ACTH]. Of the 26 patients, 75% experienced at least a second 
episode during a mean follow-up of 52  months, all of which 
again responded to medical management; 46% of patients even-
tually underwent elective surgery. If the patients remained free 
of obstruction after the initial episode for at least 8 months, the 
risk of surgery thereafter was only 17%, indicating that medical 
therapy can ultimately prevent surgery in a clinically meaningful 
proportion of patients.111
There was initially some concern regarding the use of the anti-
TNF treatment infliximab [IFX] in patients with established stric-
tures, based on two retrospective reports.112,113 Subsequently this 
was challenged by a study of 15 CD patients with obstructive 
symptoms, treated with IFX. Small intestinal contrast ultrasound 
did not show any progression of strictures and, in 80% of the 
patients responding to IFX, the stenosis completely regressed.114 
Most importantly, data in large numbers of patients from the 
TREAT registry and the ACCENT I  infliximab maintenance 
trial did not show an increased risk for the clinical occurrence 
of strictures.115 A  recent review on this topic reached the same 
conclusion.116 Most recently, the GETAID reported the use of 
adalimumab [ADA] in symptomatic small bowel strictures in CD 
in a multicentre, prospective observational cohort study. At Week 
24, 61% of the patients were free of steroids, did not require 
dilation or surgery, and did not report any adverse events. More 
than half of the responders were free of dilation or surgery even 
at year 2.117 Hence, anti-TNF appears to be a valuable treatment 
option in steroid-dependent patients who present with intestinal 
obstruction. This is supported by an observational cohort of 11 
CD patients, of whom 9 clinically responded to anti-TNF.118 Data 
on efficacy of azathioprine or 6-mercaptopurine in stricturing CD 
are lacking.
Current treatment options [steroids, immunosuppressive drugs, 
biological therapies] may relieve inflammatory lesions and related 
symptoms, but none of them has a direct anti-fibrotic effect and they 
can neither prevent nor reverse established intestinal fibrosis and 
strictures, which may present years after remission of active inflam-
mation.6,7,8,9,119,120,121,122,123 Currently, no specific medical therapy 
exists to treat fibrotic intestinal strictures.124
4.2. Endoscopic management of fibrostenosing 
Crohn’s disease
If medical therapy fails to improve obstructive symptoms, endoscopic bal-
loon dilation [EBD], strictureplasty, and resection are all equal alternatives 
in different clinical situations. The clinical situations are discussed below.
EBD has become an accepted modality for treatment of selected 
CD strictures. Main applications are short and isolated strictures 
within reach of a standard colonoscope, with many amenable stric-
tures localised to the site of the ileocaecal anastomosis after ileocae-
cal resection.125 EBD is also feasible in the upper gastrointestinal 
tract within reach of an upper endosocope126 or in the mid small 
bowel via balloon-assisted enteroscopy.25
Most commonly, through the scope balloons [TTS] are used to reach 
and pneumatically dilate strictures. In general the available reports are 
highly heterogeneous with respect to techniques used, follow-up times, 
and endpoints applied. In a systematic review and descriptive pooled 
data analysis of 33 retrospective studies, including 1463 CD patients, 
the median stricture length was 2 cm. This analysis mainly included 
post-surgical strictures and all were dilated with TTS. Endoscopic dila-
tion [EBD] was technically successful in 90% of cases. Long-term clini-
cal efficacy [median follow-up was 40.1 months], defined as being free 
of surgery, was achieved in 69.2% of the patients. A stricture length of ≤ 
5 cm was associated with a surgery-free outcome in a multivariate anal-
ysis [hazard ratio [HR]: 2.5; 95% confidence interval [CI]: 1.4–4.4].
Factors influencing outcome after endoscopic balloon dilation in 
fibrostenotic CD are largely unknown. Technically successful dila-
tion,128,129 stricture length ≤ 5 cm,127 and absence of ulcers in the 
stricture130 were positively associated with successful dilation. In 
contrast, neither CRP, endoscopic disease activity, or medical treat-
ment after dilation influenced the subsequent disease course in a 
different study.131 This was confirmed in a descriptive pooled data 
analysis with 1463 patients, in whom the presence of inflammation 
did not influence the short- or long-term outcome and also did not 
have an effect on the complication rate.127 The majority of the obser-
vations were made with anastomotic strictures. No difference was 
noted when comparing the long-term dilation efficacy or probability 
of surgery-free survival of naive versus post-surgical strictures.127
Current Practice Position on Fibrosis 15:
No drug with proven specific intestinal anti-fibrotic effect 
is available [EL5]
Current Practice Position on Fibrosis 16:
Endoscopic balloon dilation, strictureplasty, and intestinal 
resection are reasonable treatment options for short stric-
tures [EL4]
Current Practice Position on Fibrosis 17:
Appropriate, shorter strictures can be treated with endo-
scopic balloon dilation [EL 2]. Endoscopic balloon dilation 
has a high technical success rate and a favourable short- 
and long-term clinical efficacy with an acceptable compli-
cation rate [EL3].
Inflammation or ulceration at the site of the stenosis is not 
a contraindication to endoscopic balloon dilation [EL 3]
Current Practice Position on Fibrosis 18:
The presence of an abscess, phlegmon, fistula, high-
grade dysplasia, or malignancy associated with the ste-
nosis is a contraindication to endoscopic dilation and 
strictureplasty [EL 3]
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When mechanically dilating the intestine, perforation is a valid 
concern. In the above mentioned systematic review, a major compli-
cation rate [defined as bleeding, perforation, or hospitalisation] of 
2.7% was observed.127 None of the tested factors, including stric-
ture location, type, length, disease activity, balloon calibre, length, 
and pressure, were associated with complications. In a randomised 
controlled trial [RCT] with 29 paediatric patients with ED and intra-
lesional steroid injection, no complications were reported.132 To our 
knowledge, no death directly related to the procedure has ever been 
reported.
Small bowel adenocarcinoma is rare, but if overlooked can be 
fatal.133 The endoscopist should therefore have a low threshold for 
taking a biopsy before EBD. There is no convincing evidence that 
such mucosal biopsies increase the risk of perforation with subse-
quent balloon dilation.134
Intra-lesional injection of steroids has been successfully used in 
other stricturing gastrointestinal conditions, such as peptic, corrosive, 
or anastomotic strictures or fibrosis post radiotherapy.135,136,137,138 
Triamcinolone is considered an appropriate agent given its pro-
longed local effect, believed to last for 3–4 weeks.139
In CD-associated strictures, most available evidence is retro-
spective and uncontrolled. In a systematic review, the use of steroid 
injection did not make a difference to outcome.127 In a single-centre 
prospective RCT with 29 paediatric CD subjects, intra-lesional triam-
cinolone injections after EBD led to a longer time to re-dilation and to 
surgery in the steroid group compared with placebo. However, sample 
size was small and follow-up time short.132 Conversely, a prospective 
study in 13 adult CD patients was terminated early after reporting 
that triamcinolone injection led to an earlier need for re-dilation 
compared with placebo.140 However, in this series only anastomotic 
strictures were examined, the strictures were possibly long-standing 
[8–30  years after surgery], and the multicentre design could have 
influenced different endoscopic procedures among different centres. 
Small, non-controlled, case reports and series assessed the use of intra-
lesional TNF-inhibitor therapy with encouraging results.141,142
Endoscopic metallic stent insertion has been tried in few patients. 
The initial success rate was reported to be 100%, but major com-
plications, such as migration, perforation, or fistulisation were fre-
quent [67% of patients].143 In a prospective cohort study with 11 
patients, the authors concluded that the complication rate is too 
high to make this a routine treatment option, even when extract-
able stents are used.144,145 Biodegradable stents might be an emerging 
alternative.146,147 Finally, carving the stricture with a sphincterotome 
supplementing EBD has been reported in one study with no increase 
in complications,148 and this technique has been successfully com-
bined with steroid injections.149 A preliminary report indicates that 
patients receiving budesonide after dilation as opposed to dilation 
alone have a better outcome.150
If clinical symptoms recur after an initial endoscopic dilation 
of a CD-associated stricture, re-dilation is an option. In subsequent 
dilations of the same stricture, clinical efficacy as well as long-term 
outcome appear to remain unchanged.131 There is no indication that 
the rate of complication changes depending on the number of times 
a stricture is dilated.
4.3. Surgical management of fibrostenosing CD
Agreement exists that localised ileocaecal, fibrostenosing CD is 
best treated with early surgical resection in symptomatic patients 
unsuitable for endoscopic dilation [technically not feasible or 
> 5  cm].18,127,151,152,153,154 Early resection could prevent subsequent 
complications [eg fistulisation and obstruction] in high-risk patients 
with isolated ileocaecal CD, more effectively than prolonged medi-
cal treatment. Surgical recurrence after ileocolic resection is to be 
expected in 10% after 5  years and 15–20% after 10  years.155,158 
Baudry et al.159 retrospectively reviewed the charts of 132 patients 
having ileocolic resection. Those who received scheduled ileoco-
lonoscopy with tailored treatment had significantly lower clinical 
recurrence rates at 5-year follow-up.
Surgical timing for localised ileocaecal fibrostenotic CD is rele-
vant. Aratari et al.160 compared 83 patients who had surgery at time of 
the diagnosis with 124 patients who were treated medically first, and 
showed that the early surgery group had a longer clinical remission 
with less need of drugs, irrespective of disease pattern, at repeated sur-
gery [penetrating versus non-penetrating, p = 0.37]. Latella et al. also 
reported that surgery performed at diagnosis, in 115 patients with 
CD, was associated with a lower risk of repeat surgery and a longer 
time to surgery after diagnosis, compared with 375 patients managed 
medically.161 These findings were confirmed in the population-based 
study by Golovics et al.162 and by Kulungowski et al.163 in a paediatric 
population. Some studies suggest that ileocolonic strictureplasty in 
selected patients with CD of the terminal ileum is a viable alternative, 
possibly at the expense of a higher recurrence rate.164
In attempting to preserve bowel length and to reduce the risk 
of leak, patients with fibrostenosing jejuno-ileal involvement can 
be managed by means of strictureplasty. Campbell et  al.165 classi-
fied these into ‘conventional’ [Heineke–Mikulicz and Finney] and 
‘non-conventional’ strictureplasties.166,167,168,169 Agreement exists that 
short [< 10 cm] strictures are best treated with the Heineke-Mikulicz 
technique, and that Finney-like procedures are suitable for strictures 
ranging between 10 and 25 cm.18,170 A  meta-analysis including 32 
studies and 1616 patients with more than 5000 strictureplasties 
showed no differences in terms of complications and recurrences 
between conventional and non-conventional techniques.165 The 
estimated risk of surgical recurrence of strictureplasty is 35% at 
4–8 years after surgery.165,171 Indications for non-conventional stric-
tureplasties are multiple, close strictures, and patients with risks of 
Current Practice Position on Fibrosis 19:
The concomitant injection of corticosteroids, anti-TNF 
agents or the use of stents or cutting techniques can cur-
rently not be recommended [EL3]
Current Practice Position on Fibrosis 20:
Serial dilation of recurrent strictures is efficacious and 
feasible, and the choice between surgery versus repeated 
dilation should be made based on technical feasibility, 
the symptom-free interval, and patient preferences [EL3]
Current Practice Position on Fibrosis 21:
Early surgery should be the preferred option for longer 
Crohn’s disease strictures in symptomatic patients [EL3]
Current Practice Position on Fibrosis 22:
Short small bowel strictures are best treated with the 
Heineke Mikulicz technique, and longer strictures with 
Finney-like procedures or isoperistaltic strictureplasty 
[EL4]
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short bowel due to previous bowel resections.151,152,153,168,172,173 It has 
been demonstrated in a 3D geometric model that an isoperistaltic 
type of strictureplasty induces less luminal narrowing than two 
Heinecke-Mickulicz strictureplasties in a row.174 Contraindications 
are poor nutritional status and suspicion of or confirmed adeno-
carcinoma.165,173,175,176 Some advocate the routine use of tissue biop-
sies.175 In patients with a long involved segment of terminal ileum, a 
modified isoperistaltic strictureplasty over the ileocaecal valve could 
be a valid alternative to resection.
A recently published population-based study suggested that 
colonic strictures at diagnosis or during follow-up are associated 
with 3.6% and 4.9% probability of colorectal cancer at 5 and 
10 years, respectively.177 According to the ECCO evidence-based con-
sensus for endoscopy in IBD, patients with strictures detected within 
5 years should be considered at ‘high risk’, and receive surveillance 
colonoscopy yearly.178 In the CD-affected colon, malignancy is more 
frequent and the incidence is comparable to ulcerative colitis.179,180 
In a GETAID study, dysplasia or cancer was detected in 3.5% of 
patients with IBD who underwent surgery for colonic strictures.181 
Strictureplasty is therefore not recommended in colonic strictures, by 
the ECCO guidelines for the management of CD.151
Patients with localised, fibrostenosing ileocaecal CD are the 
ideal candidates for laparoscopic resection.182,183,184,185 Systematic 
reviews indicate that laparoscopic surgery is associated with less 
pain, lower morbidity, and faster recovery to work and everyday 
life.182,184,185,186,187,188 Patel et al.189 showed in their meta-analysis that 
long-term results with regard to surgical recurrence were similar 
between open and laparoscopic surgery. Incisional hernia was reduced 
in the laparoscopically treated patients.189 The rates of conversion 
vary between 6% and 10% 186. Alves et al.190 suggested that the risk is 
increased in patients with recurrent disease [OR 2] and intra-abdom-
inal abscess or fistula [OR 15]. Single-port laparoscopic surgery is a 
valid alternative for multiport laparoscopic resection. Gardenbroek 
et al.191 prospectively evaluated 63 CD patients with ileocaecal CD, 
of whom 21 and 42 received single-port and multiport laparoscopic 
resection, respectively. The authors showed that single-port ileocaecal 
resection resulted in reduced postoperative pain compared with con-
ventional laparoscopy. Advantages in terms of cosmetic results were 
reported in two other retrospective series.192,193
Smoking is the strongest and a widely accepted risk factor for 
postoperative recurrence after resection or strictureplasty for fibros-
tenosing CD.122,194 Smoking must therefore be strongly discouraged.
After surgical resection, optimisation of the medical treatment 
guided by a timely endoscopy is important to prevent recurrence of 
disease complications. Consideration should be given to following 
the ECCO consensus guidelines for follow-up after surgery and the 
medical management of CD in this situation.122
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